Zepp Health Corporation (ZEPP) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a strong financial performance with a 46% YoY revenue increase and improved operating loss. Despite slight gross margin decline, management anticipates future expansion. The share repurchase program reflects confidence in long-term growth. Although there are concerns about management's vague responses, the product pipeline and strategic initiatives, like tariff mitigation, are promising. Given the positive Q3 guidance and shareholder value focus, the stock price is likely to rise 2-8%.
Key Financial Performance
Revenue $59.4 million, a 46% year-over-year increase. This growth was driven by strong demand for the Bip 6 and Active 2 series, as well as the continued success of the T-Rex 3 series.
Gross Margin 36.2%, slightly down year-over-year due to a higher revenue proportion of lower-margin entry-level products like Amazfit Bip 6 and Active 2, and clearance of older mid-range Balance 1 products to prepare for Balance 2 launches.
Adjusted Operating Cost $26 million, compared to $25 million in Q2 2024 and $32 million last quarter. This reflects a cost-conscious approach and efforts to reduce overall operating costs.
Research and Development Expenses $10.3 million, a 4.2% year-over-year increase. The rise was due to investments in new technologies, including AI, and the development of new products.
Selling and Marketing Expenses $12 million, a 15.1% year-over-year increase but a 12.7% quarter-over-quarter decrease. The year-over-year increase was due to promotional campaigns to build brand recognition and drive sales growth.
General and Administrative Expenses $4.1 million, compared to $4.4 million in Q2 2024, reflecting a slight decrease.
Adjusted Operating Loss $4.9 million, an improvement of 42% compared to last year. This was due to cost management and operational efficiency.
Cash Balance $95 million as of June 30, 2025, compared to $103 million in Q1 2025. The decrease was influenced by timing and operating performance factors, offset by strong working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Revenue Growth: Achieved a 46% year-over-year increase in revenue to $59.4 million, driven by Amazfit brand.
New Product Launches: Introduced Balance 2 smartwatch and Helio Strap. Balance 2 priced at $299, features advanced sports tracking, heart rate variability, and recovery insights. Helio Strap offers screen-free fitness, recovery, and sleep tracking.
Product Ecosystem: Upgraded Zepp OS to Zepp OS 5.0 with AI-powered features and integrations with platforms like Strava and Training Peaks.
Global Market Expansion: Strong sales growth in the U.S. and EMEA regions, with Prime Day sales in EMEA up 60% year-over-year.
Brand Positioning: Ranked as the second most improved wearable brand in the U.S. year-over-year. Enhanced brand recognition through partnerships with athletes and sports communities.
Supply Chain Diversification: Diversified manufacturing across China, Vietnam, and evaluating NAFTA region expansion to mitigate trade uncertainties.
Cost Management: Reduced operating costs to $26 million in Q2 2025, down from $32 million last quarter.
Premiumization Strategy: Focused on premium products like Balance 2 and Helio Strap to target high-performance users and endurance sports professionals.
Marketing Strategy: Leveraged global athletes and sports events for brand promotion. Increased marketing efforts on platforms like YouTube, TikTok, and Instagram.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariff policies and trade uncertainties: The company faces challenges from evolving tariff policies and trade uncertainties, which could impact operational costs and supply chain efficiency.
Gross margin pressure: Gross margin decreased slightly year-over-year due to a higher revenue proportion of lower-margin entry-level products and clearance of older mid-range products. This could affect profitability.
Operating losses: The company reported an adjusted operating loss of $4.9 million for the quarter, highlighting ongoing challenges in covering operating expenses during lower sales seasons.
Increased R&D and marketing expenses: Year-over-year increases in R&D and marketing expenses, while necessary for competitiveness, could strain financial resources if not managed effectively.
Inventory management: Inventory levels increased slightly due to preparations for upcoming product launches, which could pose risks if demand does not meet expectations.
Debt levels and liquidity: Although the company has refinanced short-term debt into long-term instruments, overall debt levels remain a concern, and liquidity pressures could arise if cash flow does not improve.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: The company expects revenue for Q3 2025 to be in the range of $72 million to $76 million, representing a 70% to 79% year-over-year growth compared to $42.5 million in Q3 2024.
Gross Margin Projections: Gross margin is expected to expand in Q3 2025 due to the full quarter of Helio Strap and Balance 2 sales, as well as several planned new product launches.
Capital Structure and Cash Position: The company expects its overall cash balance to grow in Q3 2025 from its current levels of $95 million as of June 30, 2025.
Product Launches and Market Expansion: The company plans to expand its premium product portfolio with flagship devices designed to fortify its competitive edge and long-term business growth. New product launches are expected to drive growth and market share.
Operational Efficiency: The company remains committed to maintaining a cost-conscious approach, targeting a run rate of approximately $25 million per quarter for operating costs. Investments in R&D and marketing will continue to ensure long-term competitiveness.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: The company reconfirmed its commitment to its share repurchase program in 2025. This reflects the management's confidence in Zepp's fundamentals and long-term trajectory. The program is seen as an attractive opportunity to return value to shareholders in the current market environment.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the drivers behind the recent spike in share price?
A:The drivers include the strong market reception of Zepp's products, a successful Amazon Day, and the perception that the company is undervalued compared to its peers. Management believes continued execution of their strategy will lead to further growth and value revaluation.
Q:How many more product launches are expected in the second half of the year compared to the first half?
A:In the first half, Zepp launched entry-level products (Bip 6 and Active 2) and mid-tier products (Balance 2 and Helio Strap). While management did not provide an exact number for the second half, they hinted at exciting products in the pipeline for Q3 and Q4, comparable to or exceeding the launches in the second half of the previous year.
Q:Can gross margins reach closer to 40% for the full year?
A:Management does not provide gross margin guidance but expects gross margins to expand in the second half of the year due to a favorable product mix, including the Balance 2, Helio Strap, and upcoming products.
Q:What percentage of imports to the U.S. comes from Vietnam, and what are the current tariffs for Chinese and Vietnamese production?
A:Products shipped from China to the U.S. face tariffs just under 25%, while those from Vietnam to the U.S. have close to 0% tariffs due to a waiver. Zepp aims to maximize shipments from Vietnam to mitigate tariff impacts, which have been better than expected in the first half of the year.
Q:What sales contribution and gross margin are expected from the Helio Strap, and how will it evolve as scale ramps up?
A:The Helio Strap, launched in June, has been well-received and carries a healthy gross margin on par with the company's overall margin. It is priced at $99 and has unique value due to its performance and affordability. Supply constraints are being addressed, and full Q3 performance is expected.
Q:What are the medium-term gross margin expectations as the product mix improves?
A:Management expects gross margins to expand above 40% in the next 2-3 years as the proportion of high-end and mid-tier products increases. Entry-level products will remain a base for growth, but the focus will shift towards higher-margin products.
Q:When will supply constraints for the Helio Strap improve, and what is the capacity expectation for next year?
A:Supply constraints are expected to be resolved in Q3, allowing for full Q3 performance. Capacity expectations for next year were not specified.
Q:What are the main drivers for the strong Q3 guidance?
A:The drivers include strong performance of entry-level products (Bip and Active 2), seasonality, full-quarter contributions from Balance 2 and Helio Strap, continued growth of the T-Rex 3 flagship line, and an upcoming product launch hinted at by management.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the number of product launches in the second half of the year, gross margin guidance, and capacity expectations for the Helio Strap next year. They used vague language and avoided direct answers in these areas.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI Flow
AI runner
AI training
Active series
Amazfit Athletes
Amazfit brand
Amazfit community
Amazfit lineup
Amazfit screen
Amazon Prime
Amazon partner
App operation
Athletes date
Health
Hong Kong
Prime Day
adventure series
audience
capability
ecosystem
event
excellence
experience
foundation
functionality
future
heart rate
industry
influencers
platform
presence
sport community
subscription
support
tech
tracker
trust
volume
workout
ZEPP Transcript
Zepp Health Corporation (ZEPP) Q1 2026 Earnings Call Transcript
Neutral6-9
Zepp Health Corporation (ZEPP) Q4 2025 Earnings Call Transcript
Positive3-16
The earnings call highlighted strong financial performance with a 10% revenue increase, improved gross margins, and a 25% rise in net income. These positive financial metrics are likely to drive a positive stock price reaction. Despite the lack of specific discussions on operational updates and shareholder returns, the strong financial results and improved cash flow suggest a positive outlook. The absence of negative sentiment in the Q&A supports this view.
Zepp Health Corporation (ZEPP) Q3 2025 Earnings Call Transcript
Positive11-5
The earnings call summary indicates strong revenue growth, improved gross margins, and a solid cash position. Product launches and market expansion plans are promising. The Q&A reveals supply constraints but management is optimistic about resolving these issues and anticipates strong holiday demand. Conservative guidance and positive feedback on new products suggest potential growth. Despite some uncertainties, the overall sentiment is positive, likely resulting in a stock price increase.
Zepp Health Corporation (ZEPP) Q2 2025 Earnings Call Transcript
Positive8-4
The earnings call reveals a strong financial performance with a 46% YoY revenue increase and improved operating loss. Despite slight gross margin decline, management anticipates future expansion. The share repurchase program reflects confidence in long-term growth. Although there are concerns about management's vague responses, the product pipeline and strategic initiatives, like tariff mitigation, are promising. Given the positive Q3 guidance and shareholder value focus, the stock price is likely to rise 2-8%.
ZEPP Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
